Ketamine and Neuroinflammation: Anti-Inflammatory Mechanisms

Can ketamine cause inflammation, or does it reduce it? The answer depends on how the drug is used. At the low, monitored doses studied for depression treatment, ketamine consistently lowers markers of neuroinflammation rather than raising them. Chronic, high-dose, or unsupervised recreational ketamine use carries a separate, well-documented risk: inflammation of the bladder wall, a condition clinicians call ketamine-induced cystitis. These are two distinct physiological effects, and understanding the difference matters for anyone evaluating ketamine therapy against the drug's known risks in other settings.

Neuroinflammation, chronic low-grade inflammation within the central nervous system, has become a significant focus in depression research over the past two decades. A meaningful subset of patients with depression show elevated inflammatory markers, altered immune cell function, and neuroinflammatory changes in the brain. This inflammatory hypothesis does not replace the monoamine or glutamate-based mechanisms already tied to ketamine's antidepressant effects. It complements them, offering one explanation for why some patients do not respond to conventional antidepressants and why ketamine may work particularly well for a specific subgroup. For more on the immune signaling research behind this connection, see our coverage of ketamine, psychedelics, and brain immune signals in depression.

Understanding Neuroinflammation

What Neuroinflammation Is

Neuroinflammation is the activation of the brain's innate immune system, primarily carried out by microglia and astrocytes, along with the release of pro-inflammatory signaling molecules. Microglia are the brain's resident immune cells, and astrocytes are support cells that help regulate the brain's chemical environment. Acute neuroinflammation is a normal, protective response to injury or infection. Chronic neuroinflammation is different: it involves sustained immune activation that can damage neurons, impair synaptic function, and disrupt neurotransmitter systems over time.

Key Inflammatory Mediators

Several classes of inflammatory molecules have been implicated in depression:

• Pro-inflammatory cytokines: Interleukin-1 beta (IL-1B), interleukin-6 (IL-6), and tumor necrosis factor-alpha (TNF-alpha) are small signaling proteins that promote inflammation. Elevated levels have been consistently observed in the blood and cerebrospinal fluid of patients with depression.
• C-reactive protein (CRP): An acute-phase protein produced by the liver in response to inflammation. Elevated CRP is associated with depression severity and treatment resistance.
• Microglial activation markers: When activated, microglia release pro-inflammatory mediators that can impair neuronal function and, over time, promote neurodegeneration.
• Prostaglandins and other eicosanoids: Lipid-based inflammatory mediators that contribute to neuroinflammatory signaling.

How Inflammation Produces Depressive Symptoms

Chronic inflammation affects the brain through several interconnected pathways. Inflammatory cytokines activate an enzyme called indoleamine 2,3-dioxygenase (IDO), which diverts tryptophan away from serotonin synthesis and toward kynurenine pathway metabolites. Some of these, such as quinolinic acid, are neurotoxic and can directly activate NMDA receptors. Pro-inflammatory cytokines also impair brain-derived neurotrophic factor (BDNF) expression and disrupt synaptic plasticity, contributing to the synaptic loss seen in depression. Inflammation activates the hypothalamic-pituitary-adrenal (HPA) axis, raising cortisol levels that further damage neurons, and it generates reactive oxygen species that create oxidative stress in neuronal membranes and mitochondria. The resulting cytokine-driven sickness behavior, fatigue, social withdrawal, anhedonia, appetite changes, and sleep disturbance, overlaps significantly with the symptoms of major depression.

Evidence Linking Inflammation to Depression

Epidemiological Evidence

Large epidemiological studies point to a bidirectional relationship between inflammation and depression. Patients with chronic inflammatory conditions, including rheumatoid arthritis, inflammatory bowel disease, psoriasis, and lupus, have substantially higher rates of depression. Patients receiving interferon-alpha, a pro-inflammatory drug used to treat hepatitis C and certain cancers, develop major depression at notably high rates. According to a review published in Nature Reviews Immunology, 20 to 40 percent of patients receiving interferon-alpha therapy go on to develop major depression, one of the clearest experimental demonstrations that inflammation can cause depressive symptoms in humans. Elevated inflammatory biomarkers also predict the future onset of depression in longitudinal studies, and anti-inflammatory medications, including NSAIDs and cytokine inhibitors, have shown antidepressant effects in some clinical trials.

The Inflammatory Subtype of Depression

Not all patients with depression have elevated inflammation. Research suggests that roughly 25 to 40 percent of depressed patients show significantly elevated inflammatory markers, giving rise to the concept of an inflammatory subtype of depression, a biologically distinct form of the disorder that may respond differently to treatment. Patients with elevated inflammation tend to show greater resistance to conventional antidepressants, more prominent somatic symptoms such as fatigue and pain, more severe anhedonia, higher rates of medical comorbidities, and potentially greater responsiveness to anti-inflammatory or inflammation-modulating treatments, including cases of treatment-resistant depression where standard medications have failed.

Ketamine's Anti-Inflammatory Properties

Direct Anti-Inflammatory Effects

Research has documented anti-inflammatory activity from ketamine across several biological pathways. Ketamine reduces production of pro-inflammatory cytokines, including IL-6, TNF-alpha, and IL-1B, in laboratory studies and clinical settings, an effect observed at both anesthetic and sub-anesthetic doses. In animal models, ketamine reduces microglial activation and shifts microglia from a pro-inflammatory phenotype toward an anti-inflammatory one. Ketamine also suppresses the nuclear factor kappa B (NF-kB) signaling pathway, a master regulator of inflammatory gene expression, which reduces transcription of multiple pro-inflammatory genes at once. It further modulates Toll-like receptor (TLR) signaling, the system that helps trigger the innate immune response, which may lower the brain's inflammatory reactivity to immune challenges.

Indirect Anti-Inflammatory Effects

Beyond direct immune modulation, ketamine may reduce neuroinflammation through several indirect routes. By modulating the glutamate system, ketamine may reduce the excitotoxic component of neuroinflammation, since excessive glutamate signaling can itself activate inflammatory cascades. Its rapid effect on BDNF, which has anti-inflammatory properties in the brain, may also contribute. By improving depressive symptoms, ketamine may help normalize an overactive HPA axis that drives chronic cortisol elevation, and the resulting improvements in sleep, activity, and stress levels may reduce inflammation through behavioral pathways as well.

Clinical Evidence

Inflammation and Ketamine Response

Several clinical studies have examined the relationship between baseline inflammation and ketamine response. Research affiliated with the National Institute of Mental Health found that patients with higher baseline CRP levels showed a greater antidepressant response to ketamine, suggesting the anti-inflammatory mechanism may be particularly relevant for patients with elevated inflammation. Patients who responded to ketamine also showed larger reductions in pro-inflammatory cytokines after treatment compared to non-responders, and a 2021 meta-analysis found that ketamine treatment is associated with significant reductions in peripheral inflammatory markers. According to the National Institute of Mental Health, inflammation is one of several biological factors under active study as researchers work to understand why depression responds unevenly to available treatments. Together, these findings support the idea that ketamine's anti-inflammatory effects contribute meaningfully to its antidepressant action, particularly in the inflammatory subtype of depression.

Perioperative Applications

Ketamine's anti-inflammatory properties are well documented in surgical and critical care settings, where sub-anesthetic ketamine infusions reduce postoperative inflammation, pain, and opioid requirements. These perioperative uses provided some of the earliest clinical evidence for ketamine's immunomodulatory effects, long before its antidepressant properties were studied.

Implications for Treatment

Identifying the Inflammatory Subtype

The recognition that inflammation contributes to depression in a subset of patients has implications for personalized care. Inflammatory biomarkers such as CRP, IL-6, and TNF-alpha could potentially help identify patients most likely to respond to ketamine's anti-inflammatory mechanism. Patients with elevated inflammation who have not responded to conventional antidepressants may be particularly strong candidates for ketamine therapy; see our guide on who is a good candidate for ketamine treatment for a fuller picture of eligibility factors. Combining ketamine with other anti-inflammatory interventions, such as omega-3 fatty acids, exercise, or anti-inflammatory medications, could produce additive benefits, though this combination approach has not been formally validated in clinical trials.

Beyond Depression

Ketamine's anti-inflammatory properties have potential relevance beyond depression. Neuroinflammation is a major driver of chronic pain states, and ketamine's combined NMDA-blocking and anti-inflammatory actions may provide dual benefit there. Inflammatory processes have also been implicated in PTSD, and ketamine's anti-inflammatory effects may contribute to its efficacy in that condition. Neuroinflammation is additionally a hallmark of Alzheimer's disease, Parkinson's disease, and other neurodegenerative conditions, which has generated speculative interest in a possible neuroprotective role for ketamine, though this remains an early area of research rather than an established clinical use.

Limitations and Future Directions

The evidence for ketamine's anti-inflammatory properties is substantial, but important questions remain unresolved. Researchers have not yet quantified the relative contribution of anti-inflammatory effects versus glutamate modulation versus synaptogenesis to ketamine's overall antidepressant efficacy. The optimal dosing strategy for maximizing anti-inflammatory benefit is unknown, and whether inflammatory biomarkers can reliably guide treatment decisions in everyday clinical practice still requires prospective validation. The long-term effects of repeated ketamine dosing on immune function also need further characterization. Clinical references such as StatPearls continue to track ketamine's pharmacology and safety profile as this research evolves.

This article is for educational purposes only and does not constitute medical advice. Anyone interested in the role of inflammation in their depression, or in ketamine therapy generally, should discuss testing and treatment options with a licensed healthcare provider.